Iambic Therapeutics (NASDAQ:IAM) Stock Rated “Hold” in New Coverage at Zacks Research

Equities research analysts at Zacks Research began coverage on shares of Iambic Therapeutics (NASDAQ:IAM) in a report released on Tuesday, Zacks reports. The firm set a “hold” rating on the stock.

IAM has been the subject of several other reports. Citigroup began coverage on Iambic Therapeutics in a research report on Monday. They set a “buy” rating and a $22.00 price objective for the company. Jefferies Financial Group started coverage on shares of Iambic Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price objective on the stock. Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. JPMorgan Chase & Co. initiated coverage on shares of Iambic Therapeutics in a report on Monday. They set an “overweight” rating and a $22.00 price target for the company. Finally, Bank of America began coverage on shares of Iambic Therapeutics in a research report on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $27.25.

Iambic Therapeutics Trading Up 4.1%

Shares of NASDAQ IAM opened at $15.39 on Tuesday. Iambic Therapeutics has a 1-year low of $9.60 and a 1-year high of $25.00.

Insiders Place Their Bets

In other Iambic Therapeutics news, Director Evan Lockwood Rachlin acquired 718,750 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the acquisition, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. The trade was a 38.45% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 22.90% of the stock is owned by corporate insiders.

Iambic Therapeutics Company Profile

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.